睿昂基因(688217.SH):淋巴瘤基因重排產品可以用於淋巴瘤早期篩查 預計市佔率約20%-30%
格隆匯4月19日丨有投資者向睿昂基因(688217.SH)提問:公司在提到淋巴癌的疑似患者篩查中,預計這部分的業務量會擴大的100億以上,請問公司是對這個人羣數量怎麼考察出來的,另外,在這個業務中,請問公司目標市場佔有率能達到多少?
睿昂基因回覆:尊敬的投資者,您好。淋巴瘤基因重排產品的市場數據是根據公司對於醫院的初步調研,與國內知名醫院的相關科室主任(如皮膚科、頭頸外科等)的深入溝通得出的。公司淋巴瘤基因重排產品可以用於淋巴瘤的早期篩查,目前為國內獨家產品,預計市佔率約為20%-30%。感謝您的關注。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.